Page 54 - Read Online

Page 12 of 14 Borek et al. Rare Dis Orphan Drugs J 2023;2:5 https://dx.doi.org/10.20517/rdodj.2022.20

64. Schmidt EP, Yang Y, Janssen WJ, et al. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during
experimental sepsis. Nat Med 2012;18:1217-23. DOI PubMed PMC
65. Grechowa I, Horke S, Wallrath A, Vahl CF, Dorweiler B. Human neutrophil elastase induces endothelial cell apoptosis by activating
the PERK-CHOP branch of the unfolded protein response. FASEB J 2017;31:3868-81. DOI PubMed
66. Ushakumari CJ, Zhou QL, Wang YH, et al. Neutrophil elastase increases vascular permeability and leukocyte transmigration in
cultured endothelial cells and obese mice. Cells 2022;11:2288. DOI PubMed PMC
67. Burton VJ, Ciuclan LI, Holmes AM, Rodman DM, Walker C, Budd DC. Bone morphogenetic protein receptor II regulates pulmonary
artery endothelial cell barrier function. Blood 2011;117:333-41. DOI PubMed
68. Nickel NP, Spiekerkoetter E, Gu M, et al. Elafin reverses pulmonary hypertension via Caveolin-1-dependent bone morphogenetic
protein signaling. Am J Respir Crit Care Med 2015;191:1273-86. DOI PubMed PMC
69. Zaidi SH, You XM, Ciura S, Husain M, Rabinovitch M. Overexpression of the serine elastase inhibitor elafin protects transgenic
mice from hypoxic pulmonary hypertension. Circulation 2002;105:516-21. DOI PubMed
70. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine
elastase inhibitor. Nat Med 2000;6:698-702. DOI PubMed
71. Halbwachs-Mecarelli L, Bessou G, Lesavre P, Lopez S, Witko-Sarsat V. Bimodal distribution of proteinase 3 (PR3) surface
expression reflects a constitutive heterogeneity in the polymorphonuclear neutrophil pool. FEBS Lett 1995;374:29-33. DOI PubMed
72. Coeshott C, Ohnemus C, Pilyavskaya A, et al. Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta
from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc Natl Acad Sci
USA 1999;96:6261-6. DOI PubMed PMC
73. Hurst LA, Dunmore BJ, Long L, et al. TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and
altering NOTCH signalling. Nat Commun 2017;8:14079. DOI PubMed PMC
74. Lane KB, Machado RD, Pauciulo MW, et al; International PPH Consortium. Heterozygous germline mutations in BMPR2, encoding
a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81-4. DOI PubMed
75. Wiedow O, Lüademann J, Utecht B. Elafin is a potent inhibitor of proteinase 3. Biochem Biophys Res Commun 1991;174:6-10. DOI
PubMed
76. Ying Q, Simon SR. Kinetics of the Inhibition of Proteinase 3 by Elafin. Am J Respir Cell Mol Biol 2001;24:83-9. DOI PubMed
77. Wittamer V, Bondue B, Guillabert A, Vassart G, Parmentier M, Communi D. Neutrophil-mediated maturation of chemerin: a link
between innate and adaptive immunity. J Immunol 2005;175:487-93. DOI PubMed
78. Macvanin MT, Rizzo M, Radovanovic J, Sonmez A, Paneni F, Isenovic ER. Role of chemerin in cardiovascular diseases.
Biomedicines 2022;10:2970. DOI PubMed PMC
79. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand
from human inflammatory fluids. J Exp Med 2003;198:977-85. DOI PubMed PMC
80. Hanthazi A, Jespers P, Vegh G, et al. Chemerin added to endothelin-1 promotes rat pulmonary artery smooth muscle cell proliferation
and migration. Front Physiol 2020;11:926. DOI PubMed PMC
81. Hanthazi A, Jespers P, Vegh G, et al. Chemerin influences endothelin- and serotonin-induced pulmonary artery vasoconstriction in
rats. Life Sci 2019;231:116580. DOI PubMed
82. Peng L, Chen Y, Li Y, et al. Chemerin regulates the proliferation and migration of pulmonary arterial smooth muscle cells via the
ERK1/2 signaling pathway. Front Pharmacol 2022;13:767705. DOI PubMed PMC
83. Jankowich MD, Wu WC, Choudhary G. Association of elevated plasma endothelin-1 levels with pulmonary hypertension, mortality,
and heart failure in african american individuals: The Jackson Heart Study. JAMA Cardiol 2016;1:461-9. DOI PubMed
84. Owen CA, Campbell EJ. Angiotensin II generation at the cell surface of activated neutrophils: novel cathepsin g-mediated catalytic
activity that is resistant to inhibition. J Immunol 1998;160:1436-43. PubMed
85. de Man FS, Tu L, Handoko ML, et al. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial
hypertension. Am J Respir Crit Care Med 2012;186:780-9. DOI PubMed PMC
86. Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 1985;60:16-25.
DOI PubMed
87. Sambrano GR, Huang W, Faruqi T, Mahrus S, Craik C, Coughlin SR. Cathepsin G activates protease-activated receptor-4 in human
platelets. J Biol Chem 2000;275:6819-23. DOI PubMed
88. Rigg RA, Healy LD, Chu TT, et al. Protease-activated receptor 4 (PAR4) activity promotes platelet granule release and platelet-
leukocyte interactions. Platelets 2019;30:126-35. DOI
89. Nufer O, Corbett M, Walz A. Amino-terminal processing of chemokine ENA-78 regulates biological activity. Biochemistry
1999;38:636-42. DOI PubMed
90. Richter R, Bistrian R, Escher S, et al. Quantum proteolytic activation of chemokine CCL15 by neutrophil granulocytes modulates
mononuclear cell adhesiveness. J Immunol 2005;175:1599-608. DOI PubMed
91. Stoeckle C, Sommandas V, Adamopoulou E, et al. Cathepsin G is differentially expressed in primary human antigen-presenting cells.
Cell Immunol 2009;255:41-5. DOI PubMed
92. Farha S, Sharp J, Asosingh K, et al. Mast cell number, phenotype, and function in human pulmonary arterial hypertension. Pulm Circ
2012;2:220-8. DOI PubMed PMC
93. Bartelds B, van Loon RLE, Mohaupt S, et al. Mast cell inhibition improves pulmonary vascular remodeling in pulmonary